DiRECT (Diabetes Remission Clinical Trial)

Slides:



Advertisements
Similar presentations
M ETABOLIC S YNDROME IN P ERIONIAL D IALYSIS Dr. Sreelatha Calicut.
Advertisements

Dr. Chris Cobourn Medical Director and Surgeon Surgical Weight Loss Centre Staff Surgeon Trillium Health Centre Mississauga, Ontario.
THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)
OBESITY and CHD Nathan Wong. OBESITY AHA and NIH have recognized obesity as a major modifiable risk factor for CHD Obesity is a risk factor for development.
Effectiveness of interactive web-based lifestyle program on prevention of cardiovascular diseases risk factors in patient with metabolic syndrome: a randomized.
Liraglutide and the Preservation of Pancreatic β-Cell Function in Early Type 2 Diabetes: The LIBRA Trial Featured Article: Ravi Retnakaran, Caroline K.
Minimally Invasive Surgery Symposium Modest Weight Loss in T2 DM: Lessons from the Look AHEAD Trial Donna H. Ryan, MD Pennington Biomedical Research Center.
Look AHEAD Study Lukasz Materek Endocrinology Rounds May 20, 2012.
METABOLIC SYNDROME Dr Gerhard Coetzer. Complaint Thirsty all the time Urinating more than usual Blurred vision Tiredness.
Medical Management of obesity Perinatal ANGELS Conference Feb 17, 2005 Philip A. Kern.
Nutrition & Dietetic Service to Patients with Diabetes in West Berkshire Carolyn Jones Dietetic Team Lead.
Rapid Rise in Hypertension and Nephropathy in Youth With Type 2 Diabetes The TODAY clinical trial Featured Article: TODAY Study Group* Diabetes Care Volume.
An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia.
Obesity –Pharmacological treatments. Dietary management –A low energy,low fat diet is the most effective lifestyle intervention for weight loss Exercise.
VA/DoD 2006 Clinical Practice Guideline For Screening and Management of Overweight and Obesity Guideline Summary: Key Elements.
Obesity Surgery : Is it only for losing weight ? Joint Hospital Surgical Grand Round Simon Chu Prince of Wales Hospital.
Background  Obesity is an extremely common problem ~ 1/3 of adult Americans are obese  Patients commonly ask physicians for advice on weight loss, yet.
What Participating Providers Must Tell Consumers.
ORIGIN Outcome Reduction with an Initial Glargine Intervention (ORIGIN) Trial Overview Large international randomized controlled trial in patients with.
Diabetes update Gillian Clarke Diabetes Lead/Advanced Dietitian.
Patient-directed titration to achieve glycaemic goals in type 2 diabetes using once-daily basal insulin: results of the TITRATE randomized controlled trial.
Background There are 12 different types of medications to lower blood sugar levels in patients with type 2 diabetes. It is widely agreed upon that metformin.
‘Shaking up’ routine diabetes care: the role of the Very Low Calorie Diet Dr Anthony Dixon Elaine Jennings.
CDA exercise guidelines 150 minutes moderate – intensity (60 – 70% of max) aerobic over minimum 3 non consecutive days PLUS resistance exercise 3.
Canagliflozin Cardiovascular Safety. 2 Potential CV protection pathways of SGLT2i Diab Vasc Dis Res Mar;12(2):
DIET CONTROL  All diabetic patients should be on diet control.  Diet control is a must either the patient is taking insulin or oral therapy.  Over.
Carina Signori, DO Journal Club August 2010 Macdonald, M. et al. Diabetes Care; Jun 2010; 33,
Journal Club Julie Shah, MD Milton S Hershey Medical Center Penn State University.
Bariatric Surgery for T2DM The STAMPEDE Trial. A.R. BMI 36.5 T2DM diagnosed age 24 On Metformin, glyburide  insulin Parents with T2DM, father on dialysis.
1 Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled.
Dr Mohammed Babsail, Dr Bhavin Bakrania
R2. Sun Hee Park/Prof. Moon Chan Choi
O.V. Grubnik, V.P. Golliak, V.V. Grubnik
Nephrology Journal Club The SPRINT Trial Parker Gregg
The ACCORD Trial: Review of Design and Results
Cholesterol-Lowering Ability of a Phytostanol Softgel Supplement in Adults with Mild to Moderate Hypercholesterolemia Woodgate D et al. Lipids. 2006;41:
ACCORD Design and Baseline Characteristics
Basics of New PHASE Reporting
Key publication slides
Diabetes and Obesity Journal Club Carina Signori, D.O., M.P.H.
Intensive Lifestyle Intervention in Older Adults with Diabetes Improves Glycemic Control, Body Composition, Physical Function, and Bone Quality Alessandra.
Vanguard Phase Results for the Blood Pressure Component
Department of Internal Medicine
by Sarah Steinmetz and Amber Brouillette
New Insights from EXSCEL
Osborne K.B., Davies S.J., Coppini D.V.
Structured Education for Type 2 diabetes: expensive and unproven?
W.S.T. Swarnasri1, Noel P. Somasundaram2
CANTOS: The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study
Achieving the Clinical Potential of RAAS Blockade
Nutrition & Dietetic Service to Patients with Diabetes in West Berkshire Carolyn Jones Dietetic Team Lead.
Systolic Blood Pressure Intervention Trial (SPRINT)
Looking Beyond Glucose Control: Multifactorial Management of Type 2 Diabetes.
Effects of Intensive Blood Pressure Control on Cardiovascular Events in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk in Diabetes.
Diabetes Journal Club March 17, 2011
Section overview: Cardiometabolic risk reduction
A Multifaceted Continuing Medical Education Intervention to Improve Primary Care Physicians’ Performance In Mexico Hortensia Reyes, Ricardo Perez-Cuevas,
Reducing the Risk of Developing Diabetes
OmniHeart Feeding Study
Lecture 3 Endocrine and Metabolic Disorders “Obesity”
Goals & Guidelines A summary of international guidelines for CHD
Change in %A1C over 5 years in response to 12-week intensive lifestyle intervention used in a real-world clinical practice. Change in %A1C over 5 years.
Section overview: Cardiometabolic risk reduction
Type 2 diabetes and the DiRECT Trial
Change in (A) systolic blood pressure and (B) diastolic blood pressure over 5 years in response to 12-week intensive lifestyle intervention in a real-world.
Remission of Type 2 diabetes
Percentage of weight loss over 5 years in response to 12-week intensive lifestyle intervention in a real-world clinical practice. Percentage of weight.
Clinical responses to therapy from baseline to week 24 and end point with last observation carried forward (LOCF). Clinical responses to therapy from baseline.
Section 6: Update on lipid treatment guidelines
Nutrition Interventions to Improve Quality of Care
Presentation transcript:

DiRECT (Diabetes Remission Clinical Trial) First time randomized trial shows remission of T2DM with dietary and lifestyle intervention Lean MEJ, Leslie WS, Barnes AC, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. The Lancet 2017

DiRECT: Background & objective T2DM management is focused on pharmacological treatment Caloric restriction is beneficial for T2DM patients, but not tested in routine primary care. Study objective The DiRECT study was designed to assess whether intensive weight management can produce sustained remission of T2DM in the primary care setting. Background Current guidelines for the management of type 2 diabetes (T2DM) focus on pharmacological treatment to reduce blood glucose and the associated elevated CV risk. Life expectancy is, however, still markedly reduced in T2DM patients. There are data showing that T2DM can be returned to normal glucose control by caloric restriction, but this intervention has not been tested in routine primary care. Lean MEJ, et al. Lancet 2017

Study design (1) Main inclusion criteria Endpoint at 12 months T2DM diagnosis within the previous 6 years(*) age 20–65 years BMI: 27 - 45 kg/m2 Endpoint at 12 months Weight loss ≥15 kg DM remission defined as HbA1c <6.5% (<48 mmol/mol) after 2 months without antidiabetic medications Main exclusion criteria current insulin use HbA1c >12% weight loss of >5 kg within the past 6 months recent eGFR <30 mL/min/1.73m2 severe or unstable HF (*) most recent HbA1c value > 6.0%, if HbA1c <6.5% antidiabetic medication was continued Lean MEJ, et al. Lancet 2017

Study design (2) Control Group (N=149) ITT population (N=298) best-practice care by guidelines for up to 52 weeks Intervention Group (N=149) stop anti-diabetic and anti-hypertensive medications Total Diet Replacement 12-20 weeks Food Reintroduction 2-8 weeks The DiRECT study was an open-label, cluster-randomized trial at 49 primary care practices. Participants in the intervention group were asked to follow the Counterweight-Plus weight management program [9] and aim for achieving and maintaining at least 15 kg weight loss. A total diet replacement phase with a low energy formula diet (825-853 kcal/day; 59% carbohydrate, 13% fat, 26% protein, 2% fiber) for 3 months was used, followed by structured food reintroduction of 2-8 weeks (about 50% carbohydrate, 25% total fat, 15% protein) and an ongoing structured program with monthly visits for long-term weight loss maintenance. All oral antidiabetic drugs were discontinued on day 1 of the program, with standard protocols for reintroduction according to national guidelines. Antihypertensive drugs were withdrawn in light of the rapid BP reductions seen upon commencement of a low energy diet. At the start of food reintroduction, physical activity strategies were introduced to help participants in the intervention group to reach and maintain their individual sustainable maximum. Weight Loss Maintenance up to 52 weeks ITT: Intention-to-treat; Total Diet Replacement: 825-853 kcal/day formula; Lean MEJ, et al. Lancet 2017

Main results (1/2) Lean MEJ, et al. Lancet 2017 Percentages of patients in each group - At 12 months, weight loss ≥15 kg was seen in 26 (24%) of participants in the intervention group and in no control participants (Fisher’s exact p<0·0001). - Diabetes remission was seen in 68 (46%) of intervention participants and in six (4%) of control participants (OR: 19.7, 95%CI: 7.8-49.8, P<0.0001). - At 12 months, 74% in the intervention group were taking no antidiabetic medication, compared with 18% of controls, and in the latter group 5% commenced antidiabetic medication. IG: Intervention group; CG: Control group; DM: Diabetes Mellitus; (*) Additionally, 5% in the CG started antidiabetic medications Lean MEJ, et al. Lancet 2017

Main results (2/2) Mean change in weight (kg) Mean change in HbA1c (%) - The intervention group showed on average 10.0 kg weight loss and the control group 1.0 kg (adj difference: -8.8, 95%CI: -10.3 to -7.3, P<0.0001). - Mean HbA1c reduced by -0.9% (SD: 1.4) in the intervention group, and increased with 0.1% (SD: 1.1) in the control group (adj difference: -0.85%, 95%CI: -1.10 to -0.59, P<0.0001). P<0.0001 P<0.0001 IG: Intervention group; CG: Control group; Lean MEJ, et al. Lancet 2017

Conclusions T2DM of up to 6 years’ duration can be reversed by weight loss with help of an evidence-based structured weight management program delivered in a community setting, by routine primary care staff. Almost a quarter of participants who followed the intervention achieved at least 15 kg of weight loss at 12 months. Almost half of patients in the intervention group showed remission of diabetes, and were off antidiabetic medication. Lean MEJ, et al. Lancet 2017